Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

BI 6727  -  Volasertib

CAS 755038-65-4

C34H50N8O3  MW 618.81

Purity: 99% (optically pure)

Soluble in DMSO to 12 mM

Ordering Information:

Cat. No. Axon 1473    Prime Source

Qty1: 2 mg (research sample) / €110  $143

Qty2: 5 mg (research sample) / €155  $202

Promotion: 2 x 5 mg @ €240  $312

Qty3: 25 mg (research sample) / €580  $754

Promotion: 2 x 25 mg @ €880  $1144

Qty4: on request contract research synthesis

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   A highly potent and selective polo-like kinase (PLK) 1 inhibitor (enzyme IC50 = 0.87 nM,  EC50 = 11-37 nM on a panel of cancer cell lines), which exhibited significant anti-proliferative in multiple cancer models, including a model of taxane-resistant colorectal cancer.   A high volume of distribution, indicating good tissue penetration, and a long terminal half-life have emerged as distinct features of BI 6727, which may have a favorable effect on antitumor efficacy in vivo.   References: online   D Rudolph et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 2009, 15(9), 3094-3102. [online]   P Schöffski. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009, 14(6), 559-570. [Review]     Chemical Name: N-[trans-4-(4-Cyclopropylmethyl-piperazin-1-yl)-cyclohexyl]-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydro-pteridin-2-ylamino)-3-methoxy-benzamide

BI 6727 - Volasertib | PLK-1 inhibitor | Axon Medchem | Axon 1473 | BI6727

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.

axonmedchem.com © 2012